vs

Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and Xperi Inc. (XPER). Click either name above to swap in a different company.

PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $116.5M, roughly 1.4× Xperi Inc.). Xperi Inc. runs the higher net margin — -14.7% vs -82.0%, a 67.3% gap on every dollar of revenue. On growth, Xperi Inc. posted the faster year-over-year revenue change (-4.8% vs -22.7%). Xperi Inc. produced more free cash flow last quarter ($1.2M vs $-36.6M). Over the past eight quarters, Xperi Inc.'s revenue compounded faster (-1.0% CAGR vs -11.5%).

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

Xperi Inc. is an American multinational technology company headquartered in San Jose, California, that develops software for consumer electronics and connected cars, as well as media platforms for video service over broadband. The company is organized into four business units: Pay TV, Consumer Electronics, Connected Car, and Media Platform. Xperi's brands include DTS, HD Radio, and TiVo.

PTCT vs XPER — Head-to-Head

Bigger by revenue
PTCT
PTCT
1.4× larger
PTCT
$164.7M
$116.5M
XPER
Growing faster (revenue YoY)
XPER
XPER
+18.0% gap
XPER
-4.8%
-22.7%
PTCT
Higher net margin
XPER
XPER
67.3% more per $
XPER
-14.7%
-82.0%
PTCT
More free cash flow
XPER
XPER
$37.8M more FCF
XPER
$1.2M
$-36.6M
PTCT
Faster 2-yr revenue CAGR
XPER
XPER
Annualised
XPER
-1.0%
-11.5%
PTCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PTCT
PTCT
XPER
XPER
Revenue
$164.7M
$116.5M
Net Profit
$-135.0M
$-17.1M
Gross Margin
Operating Margin
-43.3%
-12.7%
Net Margin
-82.0%
-14.7%
Revenue YoY
-22.7%
-4.8%
Net Profit YoY
-104.8%
-137.0%
EPS (diluted)
$-1.63
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PTCT
PTCT
XPER
XPER
Q4 25
$164.7M
$116.5M
Q3 25
$211.0M
$111.6M
Q2 25
$178.9M
$105.9M
Q1 25
$1.2B
$114.0M
Q4 24
$213.2M
$122.4M
Q3 24
$196.8M
$132.9M
Q2 24
$186.7M
$119.6M
Q1 24
$210.1M
$118.8M
Net Profit
PTCT
PTCT
XPER
XPER
Q4 25
$-135.0M
$-17.1M
Q3 25
$15.9M
$-6.1M
Q2 25
$-64.8M
$-14.8M
Q1 25
$866.6M
$-18.4M
Q4 24
$-65.9M
$46.2M
Q3 24
$-106.7M
$-16.8M
Q2 24
$-99.2M
$-30.3M
Q1 24
$-91.6M
$-13.1M
Operating Margin
PTCT
PTCT
XPER
XPER
Q4 25
-43.3%
-12.7%
Q3 25
1.4%
-1.2%
Q2 25
-19.5%
-10.5%
Q1 25
82.5%
-14.4%
Q4 24
-76.2%
-11.7%
Q3 24
-27.7%
-14.0%
Q2 24
-21.5%
-18.3%
Q1 24
-21.6%
-27.2%
Net Margin
PTCT
PTCT
XPER
XPER
Q4 25
-82.0%
-14.7%
Q3 25
7.5%
-5.5%
Q2 25
-36.3%
-14.0%
Q1 25
73.7%
-16.1%
Q4 24
-30.9%
37.8%
Q3 24
-54.2%
-12.6%
Q2 24
-53.1%
-25.3%
Q1 24
-43.6%
-11.0%
EPS (diluted)
PTCT
PTCT
XPER
XPER
Q4 25
$-1.63
$-0.37
Q3 25
$0.20
$-0.13
Q2 25
$-0.83
$-0.32
Q1 25
$10.04
$-0.41
Q4 24
$-0.85
$1.02
Q3 24
$-1.39
$-0.37
Q2 24
$-1.29
$-0.67
Q1 24
$-1.20
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PTCT
PTCT
XPER
XPER
Cash + ST InvestmentsLiquidity on hand
$1.9B
$96.8M
Total DebtLower is stronger
$27.7M
Stockholders' EquityBook value
$-205.3M
$414.1M
Total Assets
$2.9B
$615.8M
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PTCT
PTCT
XPER
XPER
Q4 25
$1.9B
$96.8M
Q3 25
$1.7B
$96.8M
Q2 25
$2.0B
$95.1M
Q1 25
$2.0B
$88.0M
Q4 24
$1.1B
$130.6M
Q3 24
$1.0B
$72.7M
Q2 24
$1.1B
$92.5M
Q1 24
$884.8M
$95.2M
Total Debt
PTCT
PTCT
XPER
XPER
Q4 25
$27.7M
Q3 25
$27.7M
Q2 25
$27.7M
Q1 25
$27.7M
Q4 24
$27.7M
Q3 24
$27.7M
Q2 24
$27.7M
Q1 24
$27.7M
Stockholders' Equity
PTCT
PTCT
XPER
XPER
Q4 25
$-205.3M
$414.1M
Q3 25
$-155.8M
$421.0M
Q2 25
$-206.5M
$419.8M
Q1 25
$-185.8M
$418.9M
Q4 24
$-1.1B
$429.1M
Q3 24
$-1.1B
$377.4M
Q2 24
$-980.2M
$388.7M
Q1 24
$-893.9M
$399.1M
Total Assets
PTCT
PTCT
XPER
XPER
Q4 25
$2.9B
$615.8M
Q3 25
$2.6B
$628.8M
Q2 25
$2.6B
$629.2M
Q1 25
$2.7B
$633.5M
Q4 24
$1.7B
$667.8M
Q3 24
$1.8B
$616.2M
Q2 24
$1.9B
$619.2M
Q1 24
$1.8B
$630.4M
Debt / Equity
PTCT
PTCT
XPER
XPER
Q4 25
0.07×
Q3 25
0.07×
Q2 25
0.07×
Q1 25
0.07×
Q4 24
0.06×
Q3 24
0.07×
Q2 24
0.07×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PTCT
PTCT
XPER
XPER
Operating Cash FlowLast quarter
$-34.3M
$4.1M
Free Cash FlowOCF − Capex
$-36.6M
$1.2M
FCF MarginFCF / Revenue
-22.3%
1.0%
Capex IntensityCapex / Revenue
1.4%
2.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$702.3M
$-5.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PTCT
PTCT
XPER
XPER
Q4 25
$-34.3M
$4.1M
Q3 25
$-66.3M
$7.5M
Q2 25
$-58.3M
$10.1M
Q1 25
$870.1M
$-22.3M
Q4 24
$-30.0M
$1.2M
Q3 24
$-77.0M
$-4.6M
Q2 24
$-71.5M
$-2.1M
Q1 24
$70.8M
$-49.8M
Free Cash Flow
PTCT
PTCT
XPER
XPER
Q4 25
$-36.6M
$1.2M
Q3 25
$-69.7M
$6.7M
Q2 25
$-59.6M
$9.5M
Q1 25
$868.4M
$-23.3M
Q4 24
$-33.8M
$-510.0K
Q3 24
$-77.5M
$-5.6M
Q2 24
$-78.8M
$-2.6M
Q1 24
$61.2M
$-51.6M
FCF Margin
PTCT
PTCT
XPER
XPER
Q4 25
-22.3%
1.0%
Q3 25
-33.1%
6.0%
Q2 25
-33.3%
9.0%
Q1 25
73.8%
-20.5%
Q4 24
-15.8%
-0.4%
Q3 24
-39.4%
-4.2%
Q2 24
-42.2%
-2.2%
Q1 24
29.1%
-43.4%
Capex Intensity
PTCT
PTCT
XPER
XPER
Q4 25
1.4%
2.5%
Q3 25
1.6%
0.7%
Q2 25
0.7%
0.5%
Q1 25
0.1%
0.9%
Q4 24
1.8%
1.4%
Q3 24
0.3%
0.8%
Q2 24
4.0%
0.4%
Q1 24
4.6%
1.6%
Cash Conversion
PTCT
PTCT
XPER
XPER
Q4 25
Q3 25
-4.17×
Q2 25
Q1 25
1.00×
Q4 24
0.03×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PTCT
PTCT

Segment breakdown not available.

XPER
XPER

Pay TV$56.2M48%
Connected Car$31.3M27%
Consumer Electronics$17.2M15%
Media Platform$11.8M10%

Related Comparisons